| Can Sarepta Therapeutics shake off its summer slump? The biotechnology company's name has become nearly synonymous with the ups and downs of investing in life-sciences firms. Once a stock-market darling, Sarepta shares have tumbled roughly 50% since hitting a 52-week high in July, brought low by safety concerns related to one of its key drugs. Washed away in the selloff was $6 billion in market value.
But new data expected Friday morning concerning an experimental gene therapy for Limb-girdle muscular dystrophy could help the company out of its rut. Analysts who watch the company say investors have overlooked the treatment, which is in the early stages of research, and that the fresh data could lead to it finally getting its due.
Biotech investing is famously not for the faint of heart. Positive results in the laboratory can lead to big gains for investors, while busts can wipe out billions in market cap in the blink of an eye. Sarepta's many fans on Wall Street may be vindicated on Friday. But a disappointment could mean that the crowd of skeptics will grow.—Tim Annett Here's what else we're watching: Calling the concierge. Walmart is testing a range of employee health programs next year, including telehealth and the use of "concierges" to connect workers with doctors. The retailer is trying to contain its costs. Flavor factor. Teenagers are vaping more flavored nicotine liquids and ingesting fewer menthol cigarettes, new data show. Meanwhile, the FTC is taking a look at the marketing practices of e-cig makers. 'Queer Eye' case. After a guest on the popular reality show challenged its health-care policies, the University of Georgia said this week that it has agreed to cover medical care for gender transitions. Generic woes continue. A big cancer center said it would no longer give its patients Zantac and most of the biggest U.S. drugstores pulled it from their shelves, amid continuing contamination fears around the drug. Have you used a prescription website like Hims or Roman? Bloomberg News would like to know more about your experience. Email reporter Kristen V. Brown at kbrown340@bloomberg.net Listen up. Many antibiotics we've relied on for decades to treat infections no longer work. It's a global crisis. But where do superbugs come from? In our final episode of this season's Prognosis podcast, Bloomberg Senior Editor Jason Gale introduces a scientist searching for clues. Download it here on Apple devices, and here on Android.  Got this newsletter forwarded to you? Sign up to get it every Thursday by clicking here.
We want to hear from you. If you have feedback, questions or potential story ideas, reach out to me at tannett@bloomberg.net | 
⇉〖OpenLoad〗 2020 Superintelligence PelÃcula Completa En LÃnea released 2020. story: La vida de Carol Peters se trastorna cuando es selecci...
Post a Comment